News | April 23, 2024
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
Open a printable version of this pageEmail the URL of this page to a friend
Open a printable version of this pageEmail the URL of this page to a friend
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Submission based on results from pivotal phase III trial showing all primary endpoints met
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Global Phase-3 study initiation expected in the second half of 2024
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Subscribe To Our Newsletter & Stay Updated
